It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Autoimmune diseases result from autoantigen-mediated activation of adaptive immunity; intriguingly, autoantigen-specific T cells are also present in healthy donors. An assessment of dynamic changes of this autoreactive repertoire in both health and disease is thus warranted. Here we investigate the physiological versus pathogenic autoreactive processes in the context of Type 1 diabetes (T1D) and one of its landmark autoantigens, glutamic acid decarboxylase 65 (GAD65). Using single cell gene expression profiling and tandem T cell receptor (TCR) sequencing, we find that GAD65-specific true naïve cells are present in both health and disease, with GAD65-specific effector and memory responses showing similar ratios in healthy donors and patients. Deeper assessment of phenotype and TCR repertoire uncover differential features in GAD65-specific TCRs, including lower clonal sizes of healthy donor-derived clonotypes in patients. We thus propose a model whereby physiological autoimmunity against GAD65 is needed during early life, and that alterations of these physiological autoimmune processes in predisposed individuals trigger overt Type 1 diabetes.
Autoreactive T cells contribute to the onset of autoimmune diseases but are also detectable in healthy individuals. Here, by examining the dynamics of autoreactive T cell responses to a diabetogenic antigen, the authors show that specific phenotype and T cell receptor repertoire changes are associated with health or disease, with additional cues implicated for this transition.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 Center for Regenerative Therapies Dresden, Technische Universität Dresden, Dresden, Germany (GRID:grid.4488.0) (ISNI:0000 0001 2111 7257)
2 Guy’s Hospital, Department of Immunobiology, Faculty of Life Sciences & Medicine, King’s College London, 2nd Floor, Borough Wing, London, UK (GRID:grid.239826.4) (ISNI:0000 0004 0391 895X); Wellcome Genome Campus, Wellcome Sanger Institute, Cambridge, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382)
3 University of Santiago de Compostela, Centre for Research in Molecular Medicine and Chronic Diseases (CiMUS), Santiago de Compostela, Spain (GRID:grid.11794.3a) (ISNI:0000000109410645); Health Research Institute of Santiago de Compostela (IDIS), Santiago, Spain (GRID:grid.488911.d) (ISNI:0000 0004 0408 4897)
4 Guy’s Hospital, Department of Immunobiology, Faculty of Life Sciences & Medicine, King’s College London, 2nd Floor, Borough Wing, London, UK (GRID:grid.239826.4) (ISNI:0000 0004 0391 895X)
5 Center for Regenerative Therapies Dresden, Technische Universität Dresden, Dresden, Germany (GRID:grid.4488.0) (ISNI:0000 0001 2111 7257); Faculty of Medicine, German Center for Diabetes Research (DZD), Paul Langerhans Institute Dresden of Helmholtz Centre Munich at University Clinic Carl Gustav Carus of TU Dresden, Dresden, Germany (GRID:grid.452622.5)
6 Guy’s Hospital, Department of Immunobiology, Faculty of Life Sciences & Medicine, King’s College London, 2nd Floor, Borough Wing, London, UK (GRID:grid.239826.4) (ISNI:0000 0004 0391 895X); University of Santiago de Compostela, Centre for Research in Molecular Medicine and Chronic Diseases (CiMUS), Santiago de Compostela, Spain (GRID:grid.11794.3a) (ISNI:0000000109410645); Health Research Institute of Santiago de Compostela (IDIS), Santiago, Spain (GRID:grid.488911.d) (ISNI:0000 0004 0408 4897)